Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells
Cancer Immunology, Immunotherapy · 24.02.2024 · 73 (3)
DOI: 10.1007/s00262-024-03635-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 24.02.2024. Verfasst von Narendiran Rajasekaran und 12 weiteren Autor:innen. Beteiligte Einrichtung: Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA. nrajasekaran@coherus.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: N/A.
Abstract (Originalsprache)
Over the past decade, US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors that target programmed death-1 (PD-1) have demonstrated significant clinical benefit particularly in patients with PD-L1 expressing tumors. Toripalimab is a humanized anti-PD-1 antibody, approved by FDA for first-line treatment of nasopharyngeal carcinoma in combination with chemotherapy. In a post hoc analysis of phase 3 studies, toripalimab in combination with chemotherapy improved overall survival irrespective of PD-L1 status in nasopharyngeal carcinoma (JUPITER-02), advanced non-small cell lung cancer (CHOICE-01) and advanced esophageal squamous cell carcinoma (JUPITER-06). On further characterization, we determined that toripalimab is molecularly and functionally differentiated from pembrolizumab, an anti-PD-1 mAb approved previously for treating a wide spectrum of tumors. Toripalimab, which binds the FG loop of PD-1, has 12-fold higher binding affinity to PD-1 than pembrolizumab and promotes significantly more Th1- and myeloid-derived inflammatory cytokine responses in healthy human PBMCs in vitro. In an ex vivo system employing dissociated tumor cells from treatment naïve non-small cell lung cancer patients, toripalimab induced several unique genes in IFN-γ and immune cell pathways, showed different kinetics of activation and significantly enhanced IFN-γ signature. Additionally, binding of toripalimab to PD-1 induced lower levels of SHP1 and SHP2 recruitment, the negative regulators of T cell activation, in Jurkat T cells ectopically expressing PD-1. Taken together, these data demonstrate that toripalimab is a potent anti-PD-1 antibody with high affinity PD-1 binding, strong functional attributes and demonstrated clinical activity that encourage its continued clinical investigation in several types of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA. nrajasekaran@coherus.com.
- Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
- TopAlliance Biosciences, 9430 Key West Ave, Suite 125, Rockville, MD, 20850, USA.
- Shanghai Junshi Biosciences, Shanghai, China.
Förderung
- N/A
Zitieren
APA
Rajasekaran, N., Wang, X., Ravindranathan, S., Chin, D. J., Tseng, S. Y., Klakamp, S. L., Widmann, K., Kapoor, V. N., Vexler, V., Keegan, P., Yao, S., LaVallee, T., & Khare, S. D. (2024). Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-024-03635-3
Vancouver
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunology, Immunotherapy. 2024;73(3). doi:10.1007/s00262-024-03635-3
BibTeX
@article{Rajasekaran2024,
author = {Rajasekaran, Narendiran and Wang, Xiaoguang and Ravindranathan, Sruthi and Chin, Daniel J and Tseng, Su-Yi and Klakamp, Scott L and Widmann, Kate and Kapoor, Varun N and Vexler, Vladimir and Keegan, Patricia and Yao, Sheng and LaVallee, Theresa and Khare, Sanjay D},
title = {Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {73},
number = {3},
doi = {10.1007/s00262-024-03635-3}
}
EUVIMED